Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-19
2011-07-19
Shameem, Golam M (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S427000, C548S430000, C514S410000
Reexamination Certificate
active
07981919
ABSTRACT:
The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).
REFERENCES:
patent: 4414225 (1983-11-01), Sauter et al.
patent: 7423056 (2008-09-01), Bennani et al.
patent: 0 324 610 (1989-07-01), None
patent: WO 98/30546 (1998-07-01), None
patent: WO 99 65911 (1999-12-01), None
patent: WO 03 051883 (2003-06-01), None
Von Siavosh Mahboobi et al. “Synthesis of Carbazole Derivatives I. Reaction of 3- 2(-Nitroethenyl) indole-2-malonic Acid Esters With Michael-Acceptors” Archiv der Pharmazie, Weinheim, Germany 1995 vol. 328(1) pp. 29-38.
Siavosh Mahboobi et al. “Carbazole DerivativeS With Antimycobacterial Activity” Archiv der Pharmazie, Weinheim, Germany 1994 vol. 327(10) pp. 611-617.
Atul Agarwal et al. “Three-Dimensional Quantitative Structure-Activity Relationships of 5-HT Receptor Binding Data for Tetrahydropyridinylindole Derivatives: A Comparison of the Hansch and CoMFA Methods” Journal of Medicinal Chemistry, Athen, Georgia, USA 1993, vol. 36(25) pp. 4006-4014.
M Herslof et al. “Synthesis of a New Conformationally Defined Serotonin Homolog by Intramolecular [4+2] Cycloaddition” Tetrahedron Letter Tucson, Arizona 1987, pp. 3423-3426.
Sydney Archer et al “Synthesis and Biological Properties of Some 6H-pyrido [4, 3-b] carbazoles” Journal of Medicinal Chemistry Troy, NY 1987, vol. 30(7) pp. 1204-1210.
Silvio J Martinez et al. “Cyclic Allylamine/Enamine Systems—6. Some Reactions of 4- (indol-3-ylcarbonyl) and 4-indole-3-ylmethyl) -1, 2, 5, 6-tetrahydro-I-methylpyridines” Tetrahedron Letters Manchester, UK 1984, vol. 40(17) pp. 3339-3343.
David L Coffen et al. “Syntheses of an Antipsychotic Pyrrolo [2,3-g]isoquinoline From Areca Alkaloids” Journal of Organic Chemistry Nutley, NJ 1984, vol. 49(26) pp. 5109-5113.
Gary L Olson “Dopamine Receptor Model and Its Application in the Design of a New Class of Rigid Pyrrolo [2,3-g]isoquinoline Antipsychotics” Journal of Medicinal Chemistry Nutley, NJ 1981, vol. 24(9) pp. 1026-1034.
Lionel Chevolot et al. “Studies in the Indole Series. XII. Synthesis of Indole Alkaloids and Structural Analogs Via 5, 6-dihydropyridinium Salts” Bulletin de la Societe Chimique de France Gif-suf-Yvette, France 1976, pp. 1222-1226.
L G Rashidyan et al “Isoindoline Derivatives. I. Synthesis of Some Diamines of the Isoindoline Series” Armyanskii Khimicheskii Zhurnal Erevan, USSR 1968, vol. 21(9) pp. 793-807.
J. A. Siuciak et al., “CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity”, Neuropharmacology 52 (2007) 279-290.
L. Zhou et al., “Serotonin 2C Receptor Agonists Improve Type 2 Diabetes via Melanocortin-4 Receptor Signaling Pathways”, Cell Metab. Nov. 7, 2007; 6(5): 398-405.
S. M. Grauer et al., “Way-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics”, Psychopharmacology (2009) 204: 37-48.
D. M. Tomkins et al., “An investigation of the role of 5-HT2C receptors in modifying ethanol self-administration behaviour”, Pharmacology, Biochemistry and Behavior 71 (2002) 735-744.
A. J. Grottick et al., “Studies to Investigate the Role of 5-HT2C Receptors on Cocaine- and Food-Maintained Behavior”, JPET (2000) vol. 295, No. 3: 1183-1191.
J. CG Halford, “Obesity drugs in clinical development” Current Opinion in Investigational Drugs (2006) 7(4): 312-318.
G. A. Higgins et al., “Serotonin and drug reward: focus on 5-HT2C receptors”, European Journal of Pharmacology 480 (2003) 151-162.
M. Isaac, “Serotonergic 5-HT2C Receptors as a Potential Therapeutic Target for the Design Antiepileptic Drugs”, Current Topics in Medicinal Chemistry (2005), 5: 59-67.
J. R. Martin et al., “5-HT2C Receptor Agonists: Pharmacological Characteristics and Therapeutic Potential”, JPET (1998) vol. 286, No. 2: 913-924.
K. J. Miller, “Serotonin 5-HT2C Receptor Agonists: Potential for the Treatment of Obesity”, Molecular Interventions Oct. 2005 vol. 5, Issue 5, 282-291.
Bennani Youssef L.
Bom David C.
Robarge Michael J.
Athersys, Inc.
Shameem Golam M
Wood Phillips Katz Clark & Mortimer
LandOfFree
Tricyclic heteroaryl piperazines, pyrrolidines and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tricyclic heteroaryl piperazines, pyrrolidines and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tricyclic heteroaryl piperazines, pyrrolidines and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2737432